Luciferase Reporter Cell Line - C1498

Cancer vaccines are a promising therapeutic approach for malignancies, and their success relies on controlling tumor immunosuppression and cellular heterogeneity. Investigators evaluated the immunogenicity of a dendritic cell vaccine loaded with PLK1 peptide in combination with a multi-antigen vaccine regimen with a PD-L1 antagonist in mouse leukemia. The results showed that the PLK1122-based allogeneic vaccine generated large numbers of persistent antigen-specific CD8 T cells with significant efficacy against a wide range of tumors. The efficacy of a single PLK1122 vaccine combined with a PD-L1 antagonist in C1498 leukemia depended on the heterogeneity of MHC-I and PD-L1, whereas a peptide vaccine targeting both PLK1 and surviving and combining with a PD1 antagonist achieved complete tumor clearance and long-term survival. This suggests that PLK1 is a potential target for cancer immunotherapy and that cancer vaccines could be optimized for the treatment of multiple malignancies.

Figure 1. The researchers prepared luciferase-expressing C1498 transfectants (C1498-luc) by using recombinant lentiviruses that encode firefly-luciferase-P2A-CD90.1 cDNA. Following transduction, stable CD90.1-positive cells were isolated through flow cytometric sorting. In some cases, the C1498-luc clone was further purified by cell cloning at limiting dilutions, resulting in the C1498Homo-luc variant. (Shin AR, et al., 2020)

Enhance your research with Creative Biogene's pre-validated Luciferase Reporter Cell Line - C1498. Our ready-to-use C1498-Luciferase cell line offers reliable, high-expression luciferase activity for your assays, eliminating the need for time-consuming cloning and validation. Streamline your workflow and achieve consistent, accurate results with our optimized cell line, designed to elevate your experiments and accelerate your discoveries. Choose Creative Biogene for precision and efficiency in cancer research.